This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

High Dose Chemotherapy and Autologous Transplant for Breast Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2007 by Stanford University.
Recruitment status was:  Active, not recruiting
Information provided by:
Stanford University Identifier:
First received: September 14, 2005
Last updated: July 10, 2007
Last verified: July 2007
To determine survival outcomes for patients with chemosensitive brest cancer after treatment with high dose chemotherapy

Condition Intervention Phase
Graft vs Host Disease Procedure: high dose chemo and auto hematopoietic cell transplant Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: High Dose Chemotherapy and Peripheral Blood Progenitor Cell Rescue for Patients With Breast Cancer

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Survival

Estimated Study Completion Date: March 2005

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stage II, III or IV breast cancer
  • chemosensitive
  • adequate organ function

Exclusion Criteria:

  • prior transplant,
  • life threatening disease
  • brain metastases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00186641

United States, California
Stanford University Cancer Center
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: Ginna Laport, MD Stanford University
  More Information Identifier: NCT00186641     History of Changes
Other Study ID Numbers: BMT42
Study First Received: September 14, 2005
Last Updated: July 10, 2007

Keywords provided by Stanford University:
chronic Graft vs Host Disease

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases processed this record on August 18, 2017